Figures computed from official regulatory filings — .
Analysttarget 150 USD (+3489%)
Ownershipinsiders 0.04% · institutions 6.39% · short 9.1% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for BriaCell Therapeutics Corp. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate theclinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
3 buys— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Lustig Marc | BuyD (derivative) | n/a (No price was disclosed in the filing) | First in 12mo |
| SEC |
| Lustig Marc | Buy | $2M | conv 69First in 12mo | SEC |
| Bondarenko Jamieson | Buy | $128.2K | conv 47 | SEC |
| Williams Williams V. | BuyD (derivative) | $4.9K | First in 12mo | SEC |
| Bondarenko Jamieson | Buy | $117.7K | conv 55First in 12mo | SEC |